肺腺癌组织lncRNA CCAT1、ZEB1表达与患者临床病理参数和预后的关系

Relationship between the Expression of lncRNA CCAT1 and ZEB1 in Lung Adenocarcinoma Tissues and the Clinicopathological Parameters and Prognosis of Patients

目的:探讨肺腺癌组织中长链非编码RNA(LncRNA)结肠癌相关转录因子1(CCAT1)、锌指结合蛋白1(ZEB1)表达及与患者临床病理参数和预后的关系。方法:选取2017年2月至2020年2月期间我院收治的138例肺腺癌患者。取手术切除的癌组织以及癌旁组织(距离癌组织边缘2 cm以上)。采用实时荧光定量聚合酶链反应检测癌组织及癌旁组织中lncRNA CCAT1、ZEB1mRNA表达。分析癌组织lncRNA CCAT1、ZEB1 mRNA表达之间的相关性及与肺腺癌患者临床病理参数的关系。Kaplan-Meier法分析lncRNA CCAT1(高低表达)、ZEB1 mRNA(高低表达)肺腺癌患者的预后。多因素Cox比例风险模型分析影响肺腺癌患者预后因素。结果:肺腺癌癌组织lncRNA CCAT1、ZEB1 mRNA相对表达量分别高于癌旁组织(P<0.05)。肺腺癌患者癌组织lncRNA CCAT1与ZEB1 mRNA相对表达量呈正相关(r=0.532,P<0.05)。肿瘤TNM分期Ⅲa期、淋巴结转移肺腺癌患者lncRNA CCAT1、ZEB1 mRNA相对表达量高于Ⅰ~Ⅱ期、无淋巴结转移患者(P<0.05)。lncRNA CCAT1高表达组和低表达组3年总生存例数分别为39(60.00)、65(92.86);ZEB1 mRNA高表达组和低表达组3年总生存例数分别为41(62.12)、63(91.30)。与lncRNA CCAT1低表达组、ZEB1 mRNA低表达组相比,lncRNA CCAT1高表达组、ZEB1 mRNA高表达组3年累积生存率更低(P<0.05)。lncRNA CCAT1高表达、ZEB1 mRNA高表达以及淋巴结转移是肺腺癌患者不良预后的独立危险因素(P<0.05)。结论:肺腺癌组织中lncRNA CCAT1、ZEB1 mRNA表达上调,两者表达上调与淋巴结转移有关,且可导致不良预后,有望成为评估肺腺癌患者预后的潜在标志物。

Objective: To investigate the expression of long chain non-coding RNA(LncRNA) colon cancer related transcription factor 1(CCAT1) and zinc finger binding protein 1(ZEB1) in lung adenocarcinoma tissues and their relationship with clinicopathological parameters and prognosis of patients. Methods: 138 lung adenocarcinoma patients who were admitted to our hospital from February 2017to February 2020 were selected. Surgically resected cancer tissues and cancer adjacent tissues(more than 2 cm from the edge of cancer tissues) were taken. The expression of lncRNA CCAT1 and ZEB1 mRNA in cancer tissues and cancer adjacent tissues were detected by real-time fluorescence quantitative polymerase chain reaction. The expression of ZEB1 protein in cancer tissues and cancer adjacent tissues was detected by immunohistochemistry. The correlation between lncRNA CCAT1 and ZEB1 mRNA expression in cancer tissues and clinicopathological parameters of lung adenocarcinoma patients were analyzed. The prognosis of lncRNA CCAT1(high and low expression) and ZEB1 mRNA(high and low expression) in lung adenocarcinoma patients were analyzed by Kaplan-Meier method. The prognostic factors of lung adenocarcinoma patients were analyzed by multivariate Cox proportional hazard models. Results: The relative expression levels of lncRNA CCAT1 and ZEB1 mRNA in lung adenocarcinoma cancer tissues were higher than those in cancer adjacent tissues, respectively(P<0.05). The relative expression of lncRNA CCAT1 and ZEB1 mRNA in cancer tissues of lung adenocarcinoma patients was positively correlated(r=0.532, P<0.05). The relative expression levels of lncRNA CCAT1 and ZEB1 mRNA in lung adenocarcinoma patients with TNM stage IIIa and lymph node metastasis were higher than those in patients with stage I~II and no lymph node metastasis(P<0.05). The 3-year overall survival cases of lncRNA CCAT1 high expression group and low expression group were 39(60.00) and 65(92.86)respectively. The 3-year overall survival cases of ZEB1 mRNA high expression group and low expression group were 41(62.12) and 63(91.30) respectively. Compared with the lncRNA CCAT1 low expression group and ZEB1 mRNA low expression group. The lncRNA CCAT1 high expression group and ZEB1 mRNA high expression group had lower 3-year overall survival rates(P<0.05).high expression of lncRNA CCAT1, high expression of ZEB1 mRNA and lymph node metastasis were independent risk factors for poor prognosis in lung adenocarcinoma patients(P<0.05). Conclusion: The expression of lncRNA CCAT1 and ZEB1 mRNA in lung adenocarcinoma tissues is up-regulate, the up-regulation of both expression is related to lymph node metastasis, and can lead to poor prognosis,they are expected to become a potential marker for evaluating the prognosis of lung adenocarcinoma patients.